| |
| |
|
|
A BILL TO BE ENTITLED
|
|
|
AN ACT
|
|
|
relating to the disclosure of financial interests by and the |
|
|
regulation of advertising by health care practitioners who promote |
|
|
or facilitate the sale of drugs to consumers; providing |
|
|
administrative and civil penalties. |
|
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
|
SECTION 1. SHORT TITLE. This Act may be cited as the |
|
|
Practitioner Drug Promotion Transparency Act. |
|
|
SECTION 2. Subtitle A, Title 3, Occupations Code, is |
|
|
amended by adding Chapter 118 to read as follows: |
|
|
CHAPTER 118. PROMOTION AND SALE OF DRUGS BY HEALTH CARE |
|
|
PRACTITIONERS |
|
|
Sec. 118.001. DEFINITIONS. In this chapter: |
|
|
(1) "Advertising" means any communication made to the |
|
|
public or to a consumer, in any medium, that promotes the purchase |
|
|
or use of a drug, including a statement made on an Internet website, |
|
|
a social media platform, a newsletter, a subscription publication, |
|
|
a podcast, a broadcast, a video, a livestream, an e-mail, or a text |
|
|
message, and including a link, discount code, or other means of |
|
|
directing a consumer to a point of sale. |
|
|
(2) "Affiliated entity" means a person in which a |
|
|
health care practitioner or a member of the practitioner's |
|
|
immediate family holds a financial interest, including a pharmacy, |
|
|
telemedicine platform, distributor, wholesaler, or online |
|
|
retailer. |
|
|
(3) "Covered sale" means a sale or dispensing of a drug |
|
|
to a consumer in this state in which a health care practitioner has |
|
|
a financial interest, whether the drug is dispensed under a |
|
|
prescription drug order, under a statewide standing order or |
|
|
protocol, or without a prescription. |
|
|
(4) "Drug" has the meaning assigned by Section |
|
|
431.002, Health and Safety Code, and includes a compounded drug. |
|
|
(5) "Financial interest" means any direct or indirect |
|
|
interest in, or expectation of, remuneration that varies with or is |
|
|
contingent on the sale of a drug, including: |
|
|
(A) an ownership or investment interest in an |
|
|
affiliated entity; |
|
|
(B) a commission, affiliate fee, referral fee, |
|
|
royalty, or share of revenue or profit; |
|
|
(C) compensation attributable to a discount |
|
|
code, tracking link, or similar referral mechanism; and |
|
|
(D) a consulting, speaking, sponsorship, or |
|
|
licensing fee paid by a person that manufactures, compounds, |
|
|
distributes, or dispenses the drug. |
|
|
The term does not include ownership of less than one percent of the |
|
|
outstanding securities of a publicly traded company, or a |
|
|
reasonable fee for professional services lawfully billed to a |
|
|
patient that does not vary with the patient's purchase of a |
|
|
particular drug. |
|
|
(6) "Health care practitioner" means an individual |
|
|
licensed, certified, or registered under this title who is |
|
|
authorized to prescribe or order a drug. |
|
|
(7) "Licensing authority" means the state agency that |
|
|
issued the health care practitioner's license, certification, or |
|
|
registration. |
|
|
(8) "Unapproved use" means the use of a drug for a |
|
|
disease, condition, or purpose that is not included in the drug's |
|
|
labeling approved by the United States Food and Drug |
|
|
Administration. |
|
|
Sec. 118.002. APPLICABILITY. This chapter applies to a |
|
|
health care practitioner who, directly or through an affiliated |
|
|
entity or agent, advertises a drug in which the practitioner has a |
|
|
financial interest or facilitates a covered sale, regardless of |
|
|
whether the practitioner has a practitioner-patient relationship |
|
|
with the consumer. |
|
|
Sec. 118.003. REQUIRED DISCLOSURES IN ADVERTISING AND AT |
|
|
POINT OF SALE. (a) A health care practitioner who advertises a |
|
|
drug in which the practitioner has a financial interest shall |
|
|
include in the advertising a clear and conspicuous statement that: |
|
|
(1) the practitioner has a financial interest in the |
|
|
sale of the drug; |
|
|
(2) describes the nature of the financial interest, |
|
|
including whether the practitioner owns or is compensated by the |
|
|
seller; and |
|
|
(3) if the advertising promotes an unapproved use, |
|
|
states: "This drug has not been approved by the U.S. Food and Drug |
|
|
Administration for the use described. Talk to a licensed health |
|
|
care provider who does not profit from this sale before taking it." |
|
|
(b) Before a covered sale is completed through an Internet |
|
|
website or other remote ordering system, the seller and the health |
|
|
care practitioner shall ensure the consumer is shown, on a page the |
|
|
consumer must view before payment: |
|
|
(1) the disclosures required by Subsection (a); |
|
|
(2) the name, address, and license number of each |
|
|
health care practitioner who has a financial interest in the sale; |
|
|
(3) the name, license number, and physical address of |
|
|
the pharmacy or other person that will dispense the drug; |
|
|
(4) a statement that the consumer may obtain the drug, |
|
|
if lawfully available, from any pharmacy of the consumer's |
|
|
choosing; and |
|
|
(5) the address of an Internet website maintained by |
|
|
the licensing authority where the consumer may file a complaint. |
|
|
(c) A statement required by this section is clear and |
|
|
conspicuous only if it is: |
|
|
(1) in written advertising, displayed in the body of |
|
|
the advertising itself, and not only in a linked page, profile, or |
|
|
caption that requires the consumer to expand or click, in a type |
|
|
size at least as large as the largest type used to describe the |
|
|
drug's benefits; |
|
|
(2) in audio or video advertising, spoken at the |
|
|
beginning of the communication and, for video, also displayed on |
|
|
screen for not less than five seconds; and |
|
|
(3) in a livestream or recurring broadcast, repeated |
|
|
at least once every 15 minutes during which the drug is promoted. |
|
|
(d) The licensing authorities, in consultation with the |
|
|
Health Professions Council, may adopt rules prescribing additional |
|
|
format requirements for disclosures on specific media platforms. |
|
|
Sec. 118.004. PUBLIC REPORTING OF FINANCIAL INTERESTS. (a) |
|
|
Not later than March 1 of each year, a health care practitioner who |
|
|
had a financial interest in a covered sale or who advertised a drug |
|
|
in which the practitioner had a financial interest during the |
|
|
preceding calendar year shall file a report with the practitioner's |
|
|
licensing authority that includes: |
|
|
(1) the name and address of each affiliated entity and |
|
|
each person from whom the practitioner received remuneration |
|
|
described by Section 118.001(5); |
|
|
(2) each drug advertised or sold, and each disease or |
|
|
condition for which the practitioner promoted the drug; |
|
|
(3) the total remuneration received, reported in |
|
|
ranges prescribed by rule of the licensing authority; and |
|
|
(4) the approximate number of covered sales. |
|
|
(b) The licensing authority shall make the information |
|
|
described by Subsections (a)(1), (2), and (3) available to the |
|
|
public on its Internet website, including in any public profile of |
|
|
the practitioner maintained by the licensing authority. |
|
|
(c) Information described by Subsection (a)(4) is |
|
|
confidential, except that it may be disclosed in a disciplinary |
|
|
proceeding or an enforcement action under this chapter. |
|
|
Sec. 118.005. UNSUPPORTED CLAIMS PROHIBITED. (a) A health |
|
|
care practitioner may not, in advertising for a drug in which the |
|
|
practitioner has a financial interest, represent that the drug |
|
|
prevents, treats, mitigates, or cures a disease or condition |
|
|
unless: |
|
|
(1) that use is included in the drug's labeling |
|
|
approved by the United States Food and Drug Administration; or |
|
|
(2) at the time the representation is made, the |
|
|
representation is substantiated by competent and reliable |
|
|
scientific evidence, which must include at least one adequate and |
|
|
well-controlled clinical study in humans, published in a |
|
|
peer-reviewed scientific or medical journal, that demonstrates the |
|
|
claimed effect for that disease or condition. |
|
|
(b) A representation is not substantiated under Subsection |
|
|
(a)(2) if it is based solely on laboratory or in vitro data, animal |
|
|
studies, the drug's mechanism of action, anecdotal reports, or the |
|
|
practitioner's personal clinical experience. |
|
|
(c) The health care practitioner bears the burden of |
|
|
producing the substantiation required by Subsection (a)(2) in a |
|
|
disciplinary proceeding or enforcement action under this chapter. |
|
|
Sec. 118.006. NONPRESCRIPTION AND REMOTE SALES. (a) A |
|
|
health care practitioner may not hold a financial interest in, or |
|
|
accept remuneration from any person in connection with, the |
|
|
dispensing of a drug by a pharmacist under a statewide standing |
|
|
order or protocol that authorizes dispensing without a |
|
|
patient-specific prescription drug order, including dispensing |
|
|
under Chapter 446, Health and Safety Code. |
|
|
(b) A health care practitioner who has a financial interest |
|
|
in a covered sale may not issue a prescription drug order for that |
|
|
sale unless the practitioner has established a |
|
|
practitioner-patient relationship that meets the standard of care, |
|
|
as provided by Chapter 111. A practitioner-patient relationship is |
|
|
not established for purposes of this subsection solely by the |
|
|
consumer's completion of an online questionnaire or by the |
|
|
consumer's purchase of the drug. |
|
|
(c) Before issuing a prescription drug order for a covered |
|
|
sale, the health care practitioner shall provide the patient the |
|
|
written disclosures required by Section 118.003(b) and obtain the |
|
|
patient's acknowledgment, which may be electronic, and shall retain |
|
|
the acknowledgment in the patient's medical record. |
|
|
Sec. 118.007. EXCEPTIONS. This chapter does not apply to: |
|
|
(1) a statement, opinion, publication, testimony, or |
|
|
other communication by a health care practitioner who does not have |
|
|
a financial interest in the sale of the drug that is the subject of |
|
|
the communication; |
|
|
(2) a communication made solely to another health care |
|
|
practitioner in a professional or scientific context, including a |
|
|
peer-reviewed publication or a presentation at a professional |
|
|
conference, that does not include a point of sale or referral |
|
|
mechanism; |
|
|
(3) a drug sample provided without charge in |
|
|
compliance with federal law; |
|
|
(4) the provision or dispensing of a drug by a |
|
|
physician in compliance with Chapter 158, other than through |
|
|
advertising to the public; or |
|
|
(5) a drug administered to a patient in a hospital, |
|
|
ambulatory surgical center, or the practitioner's office as part of |
|
|
a course of treatment. |
|
|
Sec. 118.008. ENFORCEMENT; PENALTIES. (a) A violation of |
|
|
this chapter by a health care practitioner is: |
|
|
(1) unprofessional conduct and a ground for |
|
|
disciplinary action by the practitioner's licensing authority |
|
|
under the law governing the practitioner's license, including |
|
|
Section 164.051 for a physician; and |
|
|
(2) a false, misleading, or deceptive act or practice |
|
|
under Section 17.46, Business & Commerce Code, and is actionable |
|
|
under Subchapter E, Chapter 17, Business & Commerce Code. |
|
|
(b) A person who violates this chapter is liable to the |
|
|
state for a civil penalty of not more than $10,000 for each |
|
|
violation. Each advertisement disseminated and each covered sale |
|
|
made in violation of this chapter constitutes a separate violation. |
|
|
(c) The maximum civil penalty under Subsection (b) is |
|
|
doubled for a violation of Section 118.005 that relates to a disease |
|
|
or condition that is the subject of a public health disaster |
|
|
declared under Section 81.003, Health and Safety Code, or a state of |
|
|
disaster declared under Chapter 418, Government Code, if the |
|
|
violation occurs while the declaration is in effect. |
|
|
(d) The attorney general, or the district attorney or county |
|
|
attorney of a county in which a consumer who received the |
|
|
advertising or purchased the drug resides, may bring an action to |
|
|
recover a civil penalty, obtain restitution for affected consumers, |
|
|
or obtain injunctive relief under this chapter. A prosecuting |
|
|
attorney who prevails in an action under this subsection may |
|
|
recover reasonable attorney's fees and investigative costs. |
|
|
(e) A licensing authority shall refer a complaint alleging a |
|
|
violation of this chapter to the attorney general and to the |
|
|
appropriate local prosecuting attorney not later than the 30th day |
|
|
after the date the licensing authority determines the complaint is |
|
|
not frivolous. |
|
|
(f) The remedies provided by this chapter are cumulative of |
|
|
any other remedy provided by law. |
|
|
Sec. 118.009. RULES. Each licensing authority shall adopt |
|
|
rules as necessary to implement this chapter. The Health |
|
|
Professions Council shall coordinate the rules to ensure consistent |
|
|
disclosure standards across licensing authorities. |
|
|
SECTION 3. Chapter 446, Health and Safety Code, is amended |
|
|
by adding Sections 446.003 and 446.004 to read as follows: |
|
|
Sec. 446.003. REFERRAL PAYMENTS PROHIBITED; DISCLOSURE. |
|
|
(a) A pharmacist or pharmacy may not pay or offer remuneration of |
|
|
any kind to a health care practitioner, as defined by Section |
|
|
118.001, Occupations Code, or to any other person in exchange for |
|
|
referring, directing, or recruiting a consumer to purchase |
|
|
ivermectin dispensed under Section 446.001. |
|
|
(b) A pharmacist who dispenses ivermectin under Section |
|
|
446.001 shall provide the consumer a written notice stating: |
|
|
"Ivermectin has not been approved by the U.S. Food and Drug |
|
|
Administration to prevent or treat COVID-19, hantavirus, or other |
|
|
viral infections. Taking more than the recommended dose can cause |
|
|
serious harm." |
|
|
(c) A violation of Subsection (a) is grounds for |
|
|
disciplinary action by the Texas State Board of Pharmacy and |
|
|
constitutes a violation of Chapter 102, Occupations Code. |
|
|
Sec. 446.004. ANNUAL REPORT. Not later than March 1 of each |
|
|
year, each pharmacy that dispensed ivermectin under Section 446.001 |
|
|
during the preceding calendar year shall report to the Texas State |
|
|
Board of Pharmacy, in the form prescribed by the board, the number |
|
|
of doses dispensed and any adverse event reported to the pharmacy. |
|
|
The board shall publish an aggregate summary of the reports on its |
|
|
Internet website. |
|
|
SECTION 4. Section 154.006(a), Occupations Code, is amended |
|
|
by adding Subdivision (__) to read as follows: |
|
|
(__) the information required to be made public under Section |
|
|
118.004, as reported by the physician; |
|
|
SECTION 5. Not later than December 1, 2027, each licensing |
|
|
authority shall adopt the rules required by Section 118.009, |
|
|
Occupations Code, as added by this Act. |
|
|
SECTION 6. (a) Sections 118.003, 118.005, and 118.006, |
|
|
Occupations Code, as added by this Act, apply only to advertising |
|
|
disseminated or a sale made on or after January 1, 2028. |
|
|
(b) A health care practitioner is not required to file a |
|
|
report under Section 118.004, Occupations Code, as added by this |
|
|
Act, before March 1, 2029. |
|
|
(c) Section 446.003, Health and Safety Code, as added by |
|
|
this Act, applies only to remuneration paid or offered on or after |
|
|
January 1, 2028. |
|
|
SECTION 7. SEVERABILITY. If any provision of this Act or |
|
|
its application to any person or circumstance is held invalid, the |
|
|
invalidity does not affect other provisions or applications of this |
|
|
Act that can be given effect without the invalid provision or |
|
|
application, and to this end the provisions of this Act are |
|
|
severable. |
|
|
SECTION 8. This Act takes effect September 1, 2027. |